Gerry Davies

Gerry is Professor of Infection Pharmacology and Honorary Consultant in Infectious Diseases at the University of Liverpool. He is the lead clinician for TB in Liverpool and an advisor to the British Thoracic Society MDR-TB Clinical Advice Service. He ran the TB programme at Hlabisa hospital, Kwazulu/Natal, South Africa from 1994-1998, later obtaining an MSc in Epidemiology from the London School of Hygiene and a PhD in Pharmacology from the University of Liverpool. From 2007-2009, he was based at the Mahidol-Oxford Research Unit in Bangkok where he worked on anti-tuberculosis and influenza therapy and subsequently as theme leader in HIV-TB pharmacology at the Malawi-Liverpool-Wellcome Research Unit in Blantyre (2012-2014). Since 2005 he has been an editor for the Cochrane Infectious Diseases Group and is now a senior editor specialising in TB. He has extensive experience of Phase II and III clinical trials in tuberculosis in differing roles and  played a prominent role in the EU Innovative Medicines Initiative consortia PreDiCT-TB and UNITE4TB, He has served on numerous WHO policy taskforces, guidelines development groups and technical advisory groups over the last decade related to treatment of tuberculosis and since 2021 he has been a member of the UK Commission on Human Medicines Infection Expert Advisory Group.